Events › B2B Event
B2B Event
A specialized, international meeting focused on current and future lung cancer therapies, clinical trial updates, and translational research for oncologists, researchers, and pharmaceutical representatives.
Filter this event to your ICP.
Dozens of solution providers here. You probably care about 20–30. Tell us your ICP, we'll find them.
Request intelligence →Delivery within 24 hours · $1,250
⚠️ The exhibitor list for this event isn't publicly accessible yet. We'll work on it once you submit a request.
Organizer
International Association for the Study of Lung CancerNonprofit · Denver, United States · Founded 1974
Global professional organization dedicated to the study and eradication of lung cancer and other thoracic malignancies.
Why people attend
Healthcare professionals attend to learn about groundbreaking research, novel drug therapies, and clinical trials directly from experts.
Exhibitor categories
Sample matches
Filtered to a Series-B SaaS ICP. Your filter will be different.
Sample Match A
example.com
"Strong ICP match: Series B, EU expansion, VP Engineering and CTO attending."
Sample Match B
example.io
"Mid-stage SaaS with active GTM motion; product-led growth signals align with ICP."
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
Speakers
5 speakers at Targeted Therapies of Lung Cancer
Chief Scientist · Baptist Memorial Health Care Corporation
"Be Assured, the Dragon Is not Dead: Tobacco Control and the Lung Cancer Population Impact Pyramid"
Director of the Multidisciplinary Thoracic Oncology Program and the Thoracic Oncology Research Group at the Baptist Cancer Center.
Also speaking at IASLC 2027 Asia Conference on Lung Cancer, IASLC 2026 Hot Topic in Basic and Translational Science Meeting: Resistance to Immunotherapy
Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology · University of Texas MD Anderson Cancer Center
"Targeted Therapies of Lung Cancer opening keynote address"
Dr. Byers is an assistant professor at MD Anderson Cancer Center who focuses on thoracic and head and neck medical oncology, with a specific research interest in SCLC subtypes and therapeutic vulnerabilities.
Also speaking at IASLC Latin America Conference on Lung Cancer, IASLC 2027 Asia Conference on Lung Cancer
Professor · Guangdong Provincial People’s Hospital
"Zero Tolerance Strategy to Fight Lung Cancer"
Director of Guangdong Lung Cancer Institute and director of Lung Cancer Specialist Group of Chinese Society of Clinical Oncology.
Also speaking at IASLC Latin America Conference on Lung Cancer, IASLC 2027 Asia Conference on Lung Cancer, IASLC 2026 Hot Topic in Basic and Translational Science Meeting: Resistance to Immunotherapy
Medical Oncologist · Johns Hopkins University
"The Evolution of Neoadjuvant Immunotherapy for Lung Cancer"
Co-director of the Division of Upper Aerodigestive Malignancies in the Department of Oncology at Johns Hopkins University.
Also speaking at IASLC Latin America Conference on Lung Cancer, IASLC 2027 Asia Conference on Lung Cancer, IASLC 2026 Hot Topic in Basic and Translational Science Meeting: Resistance to Immunotherapy
Chief Scientist · Baptist Memorial Health Care Corporation
"Be Assured, the Dragon Is not Dead: Tobacco Control and the Lung Cancer Population Impact Pyramid"
Dr. Osarogiagbon is chief scientist at Baptist Memorial Health Care Corporation, and director of the Multidisciplinary Thoracic Oncology Program and the Thoracic Oncology Research Group at the Baptist Cancer Center, Memphis, Tennessee.
Also speaking at IASLC Latin America Conference on Lung Cancer
More events in United States
Frequently asked questions